NCT05363605: A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours |
|
|
| Terminated | 1/2 | 6 | US, RoW | [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab | Fusion Pharmaceuticals Inc. | Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer | 09/23 | 09/23 | | |
NCT03746431: A Phase 1/2 Study of [225Ac]-FPI-1434 Injection |
|
|
| Recruiting | 1/2 | 253 | Canada, US, RoW | [111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion, [225Ac]-FPI-1434 Injection single-dose | Fusion Pharmaceuticals Inc. | Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma | 06/25 | 06/26 | | |
